Bubendorf6 February 2006
BUBENDORF, Switzerland - Exceeding goals set in the planning stages of their new containment facility, CarboGen and AMCIS announced the successful completion of 16 projects since the facility began operations in July 2004. Based on increased customer demand for cytotoxic/highly potent custom synthesis development, the Swiss-based manufacturer of active pharmaceutical ingredients (APIs) has already begun expanding capacity a full year earlier than predicted.
“We have been delighted with the industry’s reception of the facility, which has allowed us to complete 16 projects in 18 months. Growth in the demand for oncology drugs has significantly exceeded our expectations. As a result, we will be expanding our capacity sooner than we originally planned in order to assure we can continue to fulfill customer needs,” said Mark Griffiths, CEO and director of operations, CarboGen and AMCIS.
CarboGen and AMCIS have experienced a steady increase in the demand for oncology drugs, which they expect to continue. “Recent industry reports tell us that with 545 drugs in the pipeline, cancer continues to be the leading area of therapeutic advancement. In our business, CarboGen and AMCIS are seeing no indications that this trend will slow down, and it is expected to increase faster than most other therapeutic areas,” said Jason Bertola, new business development director.
“The decision to expand is driven by the market as well as feedback received from customers. To enable CarboGen and AMCIS to continue growing our capabilities and to meet future customer project requirements, we will add a quality control laboratory and expand into two additional building areas, adding a total of approximately 250 square meters to our overall capacity,” added Griffiths.
The facility passed full inspections by Swiss Medic in 2005. Although the expansion isn’t slated to be operational until later this year, Bertola states that CarboGen and AMCIS have already adjusted their capacity to meet customer needs. “We now have a steady flow of projects through the facility, and a second shift has been added to accommodate the increased demand. Thanks to our initial projections for growth in this area of service, we have significant space available for quick expansion. In addition, we are actively pursuing the opportunity to offer our customers greater access to services such as formulation, chromatography, downstream processing and drug substance handling,” said Bertola.
“The future looks bright for the industry and for our facilities. We fully expect that in 2006 we will continue to see progress at an increased rate over last year,” said Griffiths.
CarboGen and AMCIS combine world-class chemistry skills to provide seamless drug substance development and commercialization services for leading pharmaceutical and biotechnology companies. We offer an array of integrated services to support faster, safer drug development with improved cost efficiency. This commitment helps our clients make decisions more quickly and progress more candidates through the pipeline in a shorter period of time.
CarboGen and AMCIS are owned by Solutia Inc., St. Louis, Missouri.
Source: CarboGen and AMCIS, Bubendorf, Switzerland